Lv2
160 积分 2022-03-28 加入
THERAPEUTIC OLIGONUCLEOTIDES, IMPURITIES, DEGRADANTS, AND THEIR CHARACTERIZATION BY MASS SPECTROMETRY
2小时前
待确认
Impurities in Oligonucleotide Drug Substances and Drug Products
2小时前
已完结
Now with oligos: antibody–oligonucleotide conjugates are the new drug modality to watch
15小时前
已完结
Phosphoramidite Platform for the Automated Synthesis of Morpholino Antisense Oligonucleotides and Their Chimeras
2个月前
已完结
Engineering considerations for next-generation oligonucleotide therapeutics
2个月前
已完结
Sustainable Approaches in Solid-phase Oligonucleotide Synthesis: Current Status and Future Directions
2个月前
已完结
Individualized Antisense Oligonucleotide Therapies: How to Approach the Challenge of Manufacturing These Oligos from a Chemistry, Manufacturing, and Control-Regulatory Standpoint
2个月前
已完结
Modern approaches to therapeutic oligonucleotide manufacturing
2个月前
已完结
Fed‐batch performance profiles for mAb production using different intensified N − 1 seed strategies are CHO cell‐line dependent
3个月前
已完结
皖公网安备34019202002308
